Rapid Diagnostics Global Market Report 2025

The rapid diagnostics market size has grown rapidly in recent years. It will grow from $32.01 billion in 2024 to $36.08 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. This historical growth was driven by the increasing burden of infectious diseases, expanding utilization of point-of-care diagnostics, growing issues with antimicrobial resistance, heightened awareness of early disease detection, and rising healthcare investments in developing nations.

The rapid diagnostics market size is expected to see rapid growth in the next few years. It will grow to $57.71 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. Key drivers for this projected growth include the rising popularity of personalized healthcare, growing implementation of AI-driven diagnostic tools, increasing consumer preference for at-home testing options, escalating healthcare infrastructure development, and a stronger emphasis on pandemic response strategies. Prominent trends anticipated during the forecast period encompass enhancements in microfluidic technologies, breakthroughs in biosensor diagnostics, integration of mobile apps with testing tools, progress in lab-on-a-chip innovations, and the evolution of multiplex diagnostic platforms.

The growing prevalence of infectious diseases is expected to drive the expansion of the rapid diagnostics market. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread from one person to another either directly or indirectly. The increase in infectious disease cases is largely attributed to greater global travel, which facilitates faster transmission and higher infection rates. Rapid diagnostics play a critical role by enabling the quick and accurate identification of pathogens, which supports timely treatment decisions, minimizes transmission, and improves patient outcomes. For example, in May 2025, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, reported that global SARS-CoV-2 activity has been increasing since mid-February 2025. According to data from sentinel sites, the test positivity rate reached 11%, a level last observed in July 2024. As such, the rising prevalence of infectious diseases is contributing to the growth of the rapid diagnostics market.

Key players in the rapid diagnostics market are prioritizing innovation and advancements, particularly in the development of rapid diagnostic testing tools that enhance accuracy, reduce turnaround times, and improve patient care in point-of-care environments. Rapid diagnostic testing tools are medical devices that swiftly detect the presence of specific diseases or conditions, often delivering results within minutes. For example, in May 2025, SEKISUI Diagnostics, a US-based medical diagnostics manufacturer, introduced the OSOM RSV Test, a rapid diagnostic tool designed to detect respiratory syncytial virus (RSV). This test is intended for professional healthcare settings and provides results in just 15 minutes. It utilizes a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen from anterior nasal swab specimens taken from symptomatic patients. The rapid results support timely and effective clinical decision-making.

In June 2023, Avacta Group, a UK-based biotechnology company, acquired Coris Bioconcept SRL for an undisclosed sum. With this acquisition, Avacta Group seeks to broaden its diagnostics portfolio and strengthen its capabilities in rapid testing technologies for infectious diseases and antimicrobial resistance. Coris Bioconcept SRL is a Belgium-based biotechnology firm specializing in the development, production, and marketing of rapid diagnostic tests.

Major players in the rapid diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Cepheid Inc., OraSure Technologies Inc., Nova Biomedical Corporation, Fujirebio Holdings Inc., Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Abingdon Health plc, Abionic SA.

North America was the largest region in the rapid diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rapid diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rapid diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rapid diagnostics are medical tests designed to swiftly detect the presence or absence of specific pathogens, conditions, or biomarkers, typically providing results within minutes to a few hours. These tests are frequently utilized at the point of care, facilitating prompt clinical decisions, early intervention, and improved patient outcomes.

The main product types in rapid diagnostics include kits, reagents, instruments, and other related products. Kits are pre-assembled diagnostic tools that contain all necessary components - such as reagents, assay devices, and instructions - for conducting specific tests accurately and efficiently. Rapid diagnostics are performed using various platforms, including immunoassays, molecular detection methods, and other technologies. They are applied across a range of testing areas such as blood glucose monitoring, infectious disease screening, cardiometabolic testing, pregnancy and fertility testing, fecal occult blood testing, coagulation testing, and toxicology screening. These diagnostic tools are distributed through multiple channels, including hospital pharmacies, physical retail stores, e-commerce platforms, and other outlets. Key end users include diagnostic laboratories, homecare settings, hospital pharmacies, and other healthcare providers.

The rapid diagnostics market research report is one of a series of new reports that provides rapid diagnostics market statistics, including the rapid diagnostics industry global market size, regional shares, competitors with the rapid diagnostics market share, detailed rapid diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the rapid diagnostics industry. This rapid diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rapid diagnostics market includes revenues earned by providing services such as quick and accurate testing for diseases, infections, and medical conditions using point-of-care diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The rapid diagnostics market consists of sales of quick diagnostic test kits and devices used for the rapid detection of diseases and medical conditions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.